Results 1 to 10 of about 42,722 (256)

mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: A multiomics analysis [PDF]

open access: goldFrontiers in Cellular and Infection Microbiology, 2022
Ethambutol (EMB) is a first-line antituberculosis drug currently being used clinically to treat tuberculosis. Mutations in the embCAB operon are responsible for EMB resistance.
Zhuhua Wu   +12 more
doaj   +2 more sources

Rapid Detection of Ethambutol-Resistant Mycobacterium tuberculosis from Sputum by High-Resolution Melting Analysis in Beijing, China

open access: greenInfection and Drug Resistance, 2020
Jun Wang,1,* Weijie Zhao,2,* Rongmei Liu,1,* Fengmin Huo,3 Lingling Dong,3 Yi Xue,3 Yufeng Wang,4 Zhongtan Xue,4 Liping Ma,1 Yu Pang3 1Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic ...
Wang J   +9 more
doaj   +1 more source

Incidence and prognostic factor of ethambutol‐related optic neuropathy: 10‐year experience in southern Taiwan

open access: yesKaohsiung Journal of Medical Sciences, 2015
To investigate the incidence and prognostic factors of ethambutol-related optic neuropathy (EON) in one medical center of southern Taiwan, a retrospective chart review study with 4803 newly diagnosed tuberculosis cases from January 2002 to July 2011 at ...
Shwu-Jiuan Sheu
exaly   +3 more sources

Ethambutol optic neuropathy [PDF]

open access: yesFrontiers in Neurology
Ethambutol is an antitubercular drug that is commonly used in the areas of the world that is endemic to tuberculosis. It is used in infections caused by Mycobacterium tuberculosis and some non-tuberculous infections caused by Mycobacterium species ...
Padmaja Sudhakar   +2 more
doaj   +2 more sources

Adverse Drug Reactions to a Daily Fixed-dose Combination Based Antituberculosis Treatment Regime in India’s National Tuberculosis Elimination Programme: A Prospective Cohort Study [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2022
Introduction: In India, the daily weight-based, Fixed Dose Combination (FDC) Antituberculosis Treatment (ATT) regime under the National Tuberculosis Elimination Programme (NTEP) was introduced, replacing the previous intermittent regime with the ...
Kapil Mate   +2 more
doaj   +1 more source

Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy

open access: yesIndian Journal of Ophthalmology, 2021
Ethambutol use may lead to permanent vision loss by inducing a dose- and duration-dependent optic neuropathy. This has been of concern to ophthalmologists and physicians both; however, ethambutol continues to be used because of its anti-mycobacterial ...
Rohit Saxena   +10 more
doaj   +1 more source

A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis [PDF]

open access: yes, 2012
PMCID: PMC3617142This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Alling, T   +7 more
core   +17 more sources

The first-line antituberculosis drugs, and their fixed-dose combination induced abnormal sperm morphology and histological lesions in the testicular cells of male mice

open access: yesFrontiers in Cell and Developmental Biology, 2022
Rifampicin (RIF), Isoniazid (INH), Ethambutol (EMB), Pyrazinamide (PZA), and/or their fixed-dose combination (FDC) are extensively prescribed in the cure of Tuberculosis (TB) globally.
Adekunle A. Bakare   +11 more
doaj   +1 more source

Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis

open access: yesTropical Medicine and Infectious Disease, 2023
Background: Patients with tuberculosis (TB) may develop multi-organ failure and require admission to intensive care. In these cases, the mortality rates are as high as 78% and may be caused by suboptimal serum concentrations of first-line TB drugs.
Francisco Beraldi-Magalhaes   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy